Hyperglycemia shields cells from Paclitaxel.
figure
posted on 2024-11-22, 18:30 authored by Sirin A. Adham, Azza Al Kalbani, Noura Al Zeheimi, Muna Al Dalali, Noor Al Kharusi, Azeeza Siddiqi, Aliya Al MaskariPanel a (MDA-mB-231 control and resistant variants) and panel b (MCF7 control and resistant variants) show quantification of the average percentage of the cell death events after exposing the control and resistant cells to 50 mM of Paclitaxel for 24 hours without FBS under the three glucose levels (25 mM, 5 mM, and 2 mM). The experiment was repeated three independent times.
(TIF)
History
Usage metrics
Categories
Keywords
specific treatment phasesglycemic load impactsexamined two groupscritical treatment stagesakt expression patterntreating breast cancerlow glucose conditionsbreast cancer subtype4xpac ), aimingsignificant cell deathglucose levels sincebreast cancer cellsvitro increased cell resistancedifferent glucose levels4xpac resistant cellsglucose concentrationscancer recurredcell linessignificant hurdledifferent drugsresistant cellstranslated clinicallystudy aimedstandard mdashedding lightresistant mdaresistant counterpartspatients resistoriginal counterpartsmcf7 cellsintricate relationshipheightened proliferationfour cyclesdifferential responsescontrol cellschemotherapeutic drugscellular responsesacquired resistance
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC